Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    gabather
Previous Study | Return to List | Next Study

Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers (GAB-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03817346
Recruitment Status : Recruiting
First Posted : January 25, 2019
Last Update Posted : January 25, 2019
Sponsor:
Collaborator:
Smerud Medical Research International AS
Information provided by (Responsible Party):
Gabather AB

Tracking Information
First Submitted Date  ICMJE December 11, 2018
First Posted Date  ICMJE January 25, 2019
Last Update Posted Date January 25, 2019
Actual Study Start Date  ICMJE December 17, 2018
Estimated Primary Completion Date March 31, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 24, 2019)
Adverse Events (AEs) [ Time Frame: Day 1 to day 3 ]
To evaluate the safety and tolerability GT-002 in healthy subjects by assessing the number, severity and type of adverse events, including changes in vital signs, physical examinations, laboratory safety tests and ECGs
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: January 24, 2019)
  • Pharmacokinetic parameter AUCt [ Time Frame: Day1 to day 3 ]
    Area under the curve from the time of dosing until the last quantifiable concentration
  • Pharmacokinetic parameter AUC0-24 [ Time Frame: Day1 to day 2 ]
    Area under the curve from the time of dosing until 24 hours post dosing
  • Pharmacokinetic parameter AUC0-infinity [ Time Frame: day 1 to day 3 ]
    Area under the curve from the time of dosing extrapolated to infinity
  • Pharmacokinetic parameter Cmax [ Time Frame: Day 1 to day 3 ]
    Maximum concentration (Cmax)
  • tmax [ Time Frame: Day 1 to day 3 ]
    Time to maximum concentration
  • t1/2 [ Time Frame: Day 1 to day 3 ]
    Apparent terminal elimination half-life
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers
Official Title  ICMJE A Phase I, Randomised, Double-blind, Placebo-controlled Study in Healthy Male Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of Ascending Single Oral Doses of GT-002
Brief Summary

This study does not target any disease or condition in itself, but is evaluating the safety, tolerability and pharmacokinetics of single oral doses of GT-002 in the setting of healthy volunteers.

A longer-term objective is to apply the findings from this study to design and later conduct a clinical development programme of GT-002 as a medication to treat schizophrenia.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Single ascending dose
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description:
Double blinde
Primary Purpose: Basic Science
Condition  ICMJE Safety and Tolerability
Intervention  ICMJE
  • Drug: GT-002
    Single ascending dose
  • Drug: Placebo oral capsule
    Comparator single ascending dose
Study Arms  ICMJE
  • Active Comparator: Experimental GT-002 SAD
    Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Six of out 8 subjects per cohort will be randomized to receive GT-002.
    Intervention: Drug: GT-002
  • Placebo Comparator: Experimental Placebo oral capsule SAD
    Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Two of out 8 subjects per cohort will be randomized to receive GT-002.
    Intervention: Drug: Placebo oral capsule
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 24, 2019)
32
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 31, 2019
Estimated Primary Completion Date March 31, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subject is willing and able to give written informed consent for participation in the study. Sufficient command of the Finnish language will be needed for informed consent and adequate communication with the study personnel.
  2. Healthy male subjects from 18 up to 45 years of age.
  3. Body mass index (BMI) from 18 kg/m2 up to 28 kg/m2.
  4. Body weight from 60 kg up to 120 kg.
  5. Clinically normal medical history, physical findings, vital signs, ECG and laboratory values as judged by the investigator at the time of the screening visit. A subject with a clinical abnormality or laboratory parameters outside of the reference range for the population being studied may be included at the investigator´s discretion provided the finding is unlikely to introduce additional risk factors, jeopardize study integrity, or to interfere with the study assessments or procedures.
  6. Subjects must be willing to use condom or other contraceptive methods with a failure rate of < 1% and refrain from donating sperm from the date of dosing until one month after last dosing.

    -

Exclusion Criteria:

  1. Current or history of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
  2. History of any type of cancer.
  3. Subjects considered unlikely to comply with study procedures, restrictions and requirements
  4. Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the administration of investigational product that is likely to introduce additional risk factors, jeopardize study integrity, or to interfere with the study assessments or procedures
  5. Any clinically significant abnormalities in clinical chemistry, haematology, coagulation or urinalysis results at the time of screening visit as judged by the investigator
  6. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody or human immunodeficiency virus (HIV)
  7. After 10 minutes of supine rest, abnormal vital signs defined as any of the following:

    1. Systolic blood pressure > 140 mm Hg (average of two measurements)
    2. Diastolic blood pressure > 90 mm Hg (average of two measurements)
    3. Heart rate < 40 or > 85 beats per minute (average of two measurements)
    4. Body temperature (auricular) ≥38oC
  8. Prolonged QTcF interval (>450 ms), clinically significant cardiac arrhythmia or any other clinically significant abnormalities in the resting ECG as judged by the investigator
  9. Intake of any medication, vitamin or mineral supplement product that could affect the outcome of the study, within 2 weeks prior to the first study treatment administration or less than 5 times the half-life of the medication. Possible prior use of enzyme inducing drugs will be considered case-by-case by the investigator.
  10. Any blood donation/blood loss > 250 ml during the 3 months prior to screening
  11. Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical trial that included drug treatment within 3 months of the administration of investigational product in this study. Subjects consented and screened but not dosed in previous phase I studies can be included in this study.
  12. Current or history of alcohol or drug abuse within the last 5 years, current excessive use of alcohol (current regular alcohol drinking of more than 24 units/week) or use of illicit drugs.
  13. Positive screen for drugs of abuse at screening or on admission to the unit or positive breath test result for alcohol at screening or on admission to the unit prior to the administration of investigational product.
  14. Known allergy to the components used in the formulation of GT-002.
  15. Current smokers or users of nicotine products. Irregular use of nicotine (e.g. smoking, snuffing, and chewing tobacco) up to five doses per week is allowed before screening visit.
  16. Intake of >5 cups of coffee/day or the corresponding amount of other caffeine containing beverages (e.g. energy drinks containing caffeine) during the study.
  17. Subjects who have planned any scheduled invasive treatment or medical/surgical procedure during the study period.

    -

Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Gender Based Eligibility: Yes
Gender Eligibility Description: Male
Ages  ICMJE 18 Years to 45 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Stefan Rehnmark, PhD +46 73-647 88 42 sr@gabather.com
Contact: Johanna Pasquariello +46 70-725 79 95 jp@gabather.com
Listed Location Countries  ICMJE Finland
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03817346
Other Study ID Numbers  ICMJE GAB-001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Gabather AB
Study Sponsor  ICMJE Gabather AB
Collaborators  ICMJE Smerud Medical Research International AS
Investigators  ICMJE
Study Chair: Yvonne Peltonen Smerud Medical Research Finland Ab/Oy
PRS Account Gabather AB
Verification Date January 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP